Building an epigenetic biomarker platform
for MND/ALS and beyond
MiND Biosciences is developing molecular tools to improve how neurodegenerative disease is understood and measured. Starting with motor neurone disease, our research connects epigenetic discovery with the development of potential blood-based tests for diagnosis and monitoring.
Turning molecular insight into practical information
Changes in gene regulation and activity can provide clues to disease biology. MiND brings together different layers of molecular information to identify patterns associated with MND/ALS and investigate their potential as biomarkers.
Our aim is to translate these discoveries into measurable information that could support clinicians and researchers.
MND/ALS is our starting point
There is a clear need for better ways to understand and monitor MND/ALS. Our initial research programme focuses on identifying disease-associated signals and assessing whether they can be translated into useful blood-based tools.
From discovery towards validation
Our initial discovery studies have identified disease-associated molecular signatures in MND/ALS models. We are progressing tissue and patient-sample studies and developing approaches to assess whether selected signals can be reliably measured in blood.
Validation is essential to understanding whether these findings can support future clinical applications.
Diagnostics experience. Scientific depth.
Co-founded by John Melki and Doug Millar, MiND brings together molecular diagnostics development and commercialisation experience with research expertise in neurodegeneration. Our Scientific Advisory Board provides guidance across epigenetics, neurology, molecular biology and translational research.
Help advance the next stage
We welcome conversations with researchers, clinicians, diagnostics developers, industry partners and investors interested in advancing our biomarker platform.
MiND’s biomarker assays are in development and are not currently available for clinical diagnosis or monitoring.
Research areas
Motor Neurone
Disease
Parkinson
Disease
Alzheimer Disease
and Tauopathies
Huntington
disease
Multiple sclerosis
and neuroinflammation
Broader neurodegenerative
and complex diseases
Schizophrenia Spectrum Disorders
Depression
Disorders
Neurodevelopmental disorders
Partner with us
MiND Biosciences is committed to advancing biomarker discovery through collaboration. We welcome opportunities to work with researchers, clinicians, industry partners and investors who share our vision for earlier, more precise diagnosis.